138 completed, 61 unknown, 30 terminated, 20 recruiting. 264 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 264 | Completed 138, Unknown 61, Terminated 30, Recruiting 20, Withdrawn 8, Active not recruiting 4, Not yet recruiting 3 |
Follow Atherosclerosis: new trials by email Literature Review of Atherosclerosis trials Research Report on Atherosclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Seltoplasmid Plus Revascularization for Diabetic Infrapopliteal Chronic Limb-Threatening Ischemia Lower-Extremity Revascularization, Donaperminogene Seltoplasmid - Chronic Limb-Threatening Ischemia, Diabetic Foot Ulcer | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 180 | 2026-10-20 | 2026-09-18 |
| Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease Secukinumab (75 mg), Standard Medical Therapy - Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease | Phase 4 | Not yet recruiting | Peking University Third Hospital | 100 | 2026-07-15 | 2026-07-15 |
| Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention Inclisiran, Alirocumab - Hypercholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 4 | Recruiting | University Medical Centre Ljubljana | 60 | 2026-05-18 | 2026-06-02 |
| Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes Cilostazol, Aspirin - Type 2 Diabetes Mellitus (T2DM), Atherosclerosis | Phase 4 | Recruiting | Seoul National University Bundang Hospital | 1200 | 2026-05-06 | 2026-07-22 |
| Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER) Carotid Ultrasound, High-intensity lipid-lowering therapy, Standard care according to ESC 2021 guidelines - Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) | Phase 4 | Recruiting | Instituto de Investigación Marqués de Valdecilla | 1944 | 2026-04-22 | 2026-11-10 |
| SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes Dapagliflozin (DAPA), Standard Care (Treatment as Usual) - Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease | Phase 4 | Recruiting | Junjie Yang | 144 | 2026-01-01 | 2026-05-29 |
| Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled Trial Evolocumab(420 mg injections) - Acute Stroke | Phase 4 | Completed | The Affiliated Hospital of Xuzhou Medical University | 60 | 2025-12-20 | 2026-07-13 |
| Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia Educational Material, Standard of care - Atherosclerotic Cardiovascular Disease | Phase 4 | Recruiting | Novartis Pharmaceuticals | 326 | 2025-11-26 | 2026-05-04 |
| Vascular Trial Associated Registry Pilot Clopidogrel (Plavix) Pharmacogenetic Test Reagents - Peripheral Arterial Disease | Phase 4 | Recruiting | Corewell Health West | 350 | 2025-10-15 | 2026-07-16 |
| ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography Aspirin, High-intensity statin, Guideline-directed statin therapy - Cardiovascular Diseases | Phase 4 | Recruiting | Jung-min Ahn | 5000 | 2025-07-24 | 2026-07-01 |
| LDL Cholesterol Reduction Following Ezetimibe Initiation Ezetimibe - Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Risk | Phase 4 | Recruiting | Universidade do Porto | 100 | 2025-06-01 | 2026-09-24 |
| Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Auryon Atherectomy System, Balloon Angioplasty - Peripheral Arterial Diseases | Phase 4 | Recruiting | Angiodynamics, Inc. | 224 | 2025-04-21 | 2026-01-08 |
| LATAM LOWERS LDL-C Usual care, KJX839 - Hypercholesterolaemia | Phase 4 | Recruiting | Novartis Pharmaceuticals | 520 | 2025-02-11 | 2025-12-30 |
| Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis Atorvastatin, Placebo - Atherosclerosis, Melanoma | Phase 4 | Not yet recruiting | Erasmus Medical Center | 140 | 2025-02-01 | 2025-01-22 |
| VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease Inclisiran - Atherosclerotic Cardiovascular Disease | Phase 4 | Active not recruiting | Duke University | 130 | 2024-12-16 | 2026-07-29 |
| Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease Influenza Vaccination - Coronary Artery Disease, Inflammatory Response | Phase 4 | Completed | University Hospital, Tours | 47 | 2024-10-21 | 2025-11-21 |
| A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease. Inclisiran sodium, BPA - Hypercholesterolemia | Phase 4 | Completed | Novartis Pharmaceuticals | 402 | 2024-06-21 | 2026-07-29 |
| Clopidogrel Versus Cilostazol on Vessels Clopidogrel, Cilostazol - Type 2 Diabetes, Atherosclerosis | Phase 4 | Recruiting | Seoul National University Bundang Hospital | 120 | 2024-04-16 | 2026-05-05 |
| Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) Statin, Aspirin tablet, Nexlizet - Coronary Artery Disease, Atherosclerosis | Phase 4 | Withdrawn | University of Louisville | 2024-03-01 | 2025-03-17 | |
| VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization rivaroxaban 2.5 mg bid + aspirin 100 mg, clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures - Peripheral Arterial Disease, Venous Thormboembolism | Phase 4 | Recruiting | Science Valley Research Institute | 100 | 2024-02-24 | 2025-03-12 |
Showing 20 of 264. Sign in to see all of them.
Peripheral Arterial Disease (85) · Coronary Artery Disease (38) · Cardiovascular Diseases (29) · Diabetes Mellitus, Type 2 (26) · Inflammation (23) · Chronic Limb-Threatening Ischemia (20) · Hypercholesterolemia (19) · Intermittent Claudication (18) · Coronary Disease (14) · Dyslipidemias (12) · Peripheral Vascular Diseases (12) · Diabetes Mellitus (11) · Hypertension (10) · Vascular Diseases (10)
Arterial Occlusive Diseases (260) · Arteriosclerosis (260) · Vascular Diseases (254) · Cardiovascular Diseases (235) · Pathological Conditions, Signs and Symptoms (88) · Peripheral Vascular Diseases (87) · Nutritional and Metabolic Diseases (72) · Metabolic Diseases (71) · Pathologic Processes (66) · Heart Diseases (63) · Myocardial Ischemia (60) · Glucose Metabolism Disorders (43) · Endocrine System Diseases (39) · Coronary Disease (35)
Aspirin (32) · Clopidogrel (22) · Atorvastatin (20) · Rosuvastatin Calcium (14) · Ezetimibe (13) · Simvastatin (12) · Cilostazol (9) · Rivaroxaban (9) · evolocumab (9) · Metformin (6) · Niacin (6) · Ticagrelor (6) · Ezetimibe, Simvastatin Drug Combination (5) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (5) · Ramipril (5)
Flanders Medical Research Program (8) · Organon and Co (8) · Seoul National University Bundang Hospital (7) · Radboud University Medical Center (6) · Boston Scientific Corporation (4) · Medical University of Vienna (4) · Novartis Pharmaceuticals (4) · Peking Union Medical College Hospital (4) · University Hospital, Angers (4) · Yuhan Corporation (4) · Asan Medical Center (3) · Baylor College of Medicine (3) · Johns Hopkins University (3) · Korea University Anam Hospital (3) · National Cheng-Kung University Hospital (3)
United States (67) · South Korea (25) · China (15) · Italy (15) · Belgium (11) · France (10) · Germany (10) · Netherlands (10) · Austria (7) · Brazil (7) · Spain (7) · Switzerland (7) · Canada (6) · Taiwan (6) · United Kingdom (6)
Marc Bosiers, MD (5) · Bronwyn A Kingwell, PhD (3) · Charles H Hennekens, MD, DrPH (2) · David Mazer, MD (2) · G Rongen, MD PhD (2) · Hanafiah Harunarashid, MS (2) · Leonardo Clavijo, MD, PhD (2) · Liu Changwei, bachelor (2) · Martin Schillinger, MD (2) · Matthew Budoff, MD (2) · Nicolas Rodondi, MD MAS (2)
PMID 40875095, PMID 42573020, PMID 11789964, PMID 12495171, PMID 12893742, PMID 15290734, PMID 15353407, PMID 16163360, PMID 16245247, PMID 16670135, PMID 16672699, PMID 16749654, PMID 16893434, PMID 17398308, PMID 17407633, PMID 17552046, PMID 17556718, PMID 17643572, PMID 17761367, PMID 17804683, PMID 18226326, PMID 18270378, PMID 18451347, PMID 18545068, PMID 18653575, PMID 18667204, PMID 18765395, PMID 18765432, PMID 18940900, PMID 18997198, PMID 19006254, PMID 19075102, PMID 19423946, PMID 19447387, PMID 19557844, PMID 19915217, PMID 20145342, PMID 20354489, PMID 20393508, PMID 20399059, PMID 20452396, PMID 20484828, PMID 20507582, PMID 20630463, PMID 20668482, PMID 20837928, PMID 21146749, PMID 21177297, PMID 21227624, PMID 21270185
2018 (2), 2017 (1), 2025 (1), I01CX001449 (1), K23HL151871 (1), K23HL169929 (1), R01HL063895 (1), R01HL075824 (1), R01HL082638 (1), R01HL128816 (1)